Author

Theresa Reutter

Observed name: T. Reutter

Institution: Asklepios Klinik Altona

Observed institutions: University of Cologne, Asklepios Klinik Altona, University Hospital Cologne, Asklepios

ORCID: 0009-0001-5153-7049

Observed ORCID: 0009-0001-5153-7049

OpenAlex ID: A5006700355

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

2024 · S. Michels, B. Massutí, et al. · ESMO Open · 11

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report

2023 · Theresa Reutter, Jana Fassunke, et al. · JCO Precision Oncology · 3

FIND: A Phase II Study to Evaluate the Efficacy and Safety of Erdafitinib in FGFR -Altered NSCLC

2026 · Lucia Nogova, Florian Malchers, et al. · Clinical Cancer Research

Works count: 3

Citation count: 14

H-index: 2

I10-index: 1